In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.

Abstract : Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy derived from plasmacytoid dendritic cells. There is currently no accepted standard of care for treating this neoplasm, and therapeutic strategies have never been prospectively evaluated. Since blastic plasmacytoid dendritic cell neoplasm cells express high levels of interleukin-3 receptor α chain (IL3-Rα or CD123), antitumor effects of the interleukin-3 receptor-targeted drug SL-401 against blastic plasmacytoid dendritic cell neoplasm were evaluated in vitro and in vivo. The cytotoxicity of SL-401 was assessed in patient-derived blastic plasmacytoid dendritic cell neoplasm cell lines (CAL-1 and GEN2.2) and in primary blastic plasmacytoid dendritic cell neoplasm cells isolated from 12 patients using flow cytometry and an in vitro cytotoxicity assay. The cytotoxic effects of SL-401 were compared to those of several relevant cytotoxic agents. SL-401 exhibited a robust cytotoxicity against blastic plasmacytoid dendritic cell neoplasm cells in a dose-dependent manner. Additionally, the cytotoxic effects of SL-401 were observed at substantially lower concentrations than those achieved in clinical trials to date. Survival of mice inoculated with a blastic plasmacytoid dendritic cell neoplasm cell line and treated with a single cycle of SL-401 was significantly longer than that of untreated controls (median survival, 58 versus 17 days, P<0.001). These findings indicate that blastic plasmacytoid dendritic cell neoplasm cells are highly sensitive to SL-401, and support further evaluation of SL-401 in patients suffering from blastic plasmacytoid dendritic cell neoplasm.
Type de document :
Article dans une revue
Haematologica, Ferrata Storti Foundation, 2015, 100 (2), pp.223-30
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-01146053
Contributeur : Philippe Saas <>
Soumis le : lundi 27 avril 2015 - 15:44:07
Dernière modification le : vendredi 27 juillet 2018 - 15:30:06
Document(s) archivé(s) le : mercredi 19 avril 2017 - 07:48:21

Fichiers

Acute Myeloid Leukemia _ Angel...
Fichiers produits par l'(les) auteur(s)

Identifiants

  • HAL Id : inserm-01146053, version 1
  • PUBMED : 25381130

Citation

Fanny Angelot-Delettre, Anne Roggy, Arthur Frankel, Baptiste Lamarthee, Estelle Seilles, et al.. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.. Haematologica, Ferrata Storti Foundation, 2015, 100 (2), pp.223-30. 〈inserm-01146053〉

Partager

Métriques

Consultations de la notice

307

Téléchargements de fichiers

284